http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110570903-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B20-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H70-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-565 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16H70-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B20-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-565 |
| filingDate | 2019-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110570903-B |
| titleOfInvention | Medicine for improving activity of mesocerebral substantia nigra dopamine neurons and preventing and treating Parkinson's disease |
| abstract | The invention provides a medicine for improving the activity of mesocerebral substantia nigra dopamine neurons and preventing and treating Parkinson's disease, which is fulvestrant. The invention also provides a method for screening and improving the activity of the mesocerebral substantia nigra dopamine neuron for preventing and treating the Parkinson disease, which adopts a bioinformatics method of weighting gene coexpression network analysis and identification of a biological related difference coexpression module to match genes closely related to the Parkinson disease into the gene network module to obtain the gene coexpression module related to the Parkinson disease, and screens and obtains the medicine capable of obviously reversing the abnormally expressed genes in the module through a correlation map database and difference gene expression spectrum data between samples of the brain substantia nigra brain region in a Parkinson disease person and a normal control group. The invention overcomes the limitation of a single channel or target spot, and utilizes the CMAP database to screen approved clinical drugs, thereby saving time, money and labor cost and being more beneficial to developing safe and effective drugs. |
| priorityDate | 2019-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 241.